Bleeding rates raise questions about Pradaxa dosing in elderly
This article was originally published in Scrip
Further data on bleeding rates with Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran) in the elderly in the US have raised concerns over the one-size-fits-all dose regimen approved by the FDA.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.